Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

In the first study of vitamin K and Non-Hodgkin lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing Non-Hodgkin lymphoma.

20 Apr 2010

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Cell Therapeutics, Inc. today announced that it met with and received feedback from the rapporteurs and the European Medicines Agency's medical reviewers regarding a proposed filing of a Marketing Authorization Application for pixantrone in the European Union to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

19 Apr 2010

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus and progression to cancers other than hepatocellular carcinoma.

16 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

Cancer drug, antiviral agent can eradicate active virus infection and tumor: UNC School of Medicine

Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists.

13 Apr 2010

Common drug used to treat Burkitt lymphoma can activate EBV: Study

Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists.

13 Apr 2010

TriLink partners with Cedarlane to enhance distribution of its products in Canada

TriLink BioTechnologies, has entered into an agreement with Cedarlane Corporation, a Canadian based research biotechnology company, for the sale and distribution of its modified nucleoside triphosphates, custom chemistry and oligonucleotide products.

9 Apr 2010

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").

9 Apr 2010

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

7 Apr 2010

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), City of Hope Cancer Center (Duarte, Calif.) and the University of Chicago (Chicago, Ill).

7 Apr 2010

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the fourth quarter and fiscal year ended December 31, 2009.

5 Apr 2010

Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

5 Apr 2010

Cancer Prevention Coalition's statement on new nominated NCI Director

Last Wednesday, the White House nominated Nobel Laureate Harold Varmus as Director of the National Cancer Institute.

3 Apr 2010

Agent Orange exposure: VA adds three new illnesses to list of health problems

Well over 100,000 Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to qualify for disability pay under a proposed regulation published by the Department of Veterans Affairs (VA) that adds three new illnesses to the list of health problems found to be related to Agent Orange and other herbicide exposures.

27 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

CT colonography screening identifies unsuspected cancer outside of colon

A new, large-scale study of more than 10,000 adults found that more than one in every 200 asymptomatic people screened with CT colonography, or virtual colonoscopy, had clinically unsuspected malignant cancer and more than half of the cancers were located outside the colon. The findings were published in the April issue of the journal Radiology.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

NerPharMa facility receives FDA approval to manufacture CTI's drug pixantrone

Cell Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has completed its inspection of the facility at NerPharMa (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences Srl, in Nerviano, Italy), which manufactures the CTI's drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product.

8 Mar 2010

Second AACR cancer research conference to be hosted in Dead Sea, Jordan

The second American Association for Cancer Research Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic provides attendees with an overview of the most advanced cancer research in a variety of fields, including the tumor microenvironment, microRNAs, signal transduction and novel therapeutic development.

5 Mar 2010

Non Hodgkin's Lymphoma News and Research

Further Reading

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Cancer drug, antiviral agent can eradicate active virus infection and tumor: UNC School of Medicine

Common drug used to treat Burkitt lymphoma can activate EBV: Study

TriLink partners with Cedarlane to enhance distribution of its products in Canada

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Rebirth of the cursed drug Thalidomide

Cancer Prevention Coalition's statement on new nominated NCI Director

Agent Orange exposure: VA adds three new illnesses to list of health problems

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

CT colonography screening identifies unsuspected cancer outside of colon

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

NerPharMa facility receives FDA approval to manufacture CTI's drug pixantrone

Second AACR cancer research conference to be hosted in Dead Sea, Jordan

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News